URGN Q2 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+3403.2% YoY

Gross Profit

$12M89.1% margin

Operating Income

-$23M-175.1% margin

Net Income

-$26M-201.2% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

+74.1%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$154M

Total Liabilities

$97M

Stockholders' Equity

$56M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$372,000	+3403.2%
Gross Profit	$12M	$324,000	+3481.8%
Operating Income	-$23M	-$32M	+28.2%
Net Income	-$26M	-$31M	+16.4%